What's changing in longevity—and what it means for the businesses building it. Read the latest briefing or catch up on earlier issues.
The newsletter is always free.
Newsletter #4 · Sep 10, 2026
Blood tests, care services, doctor-led memberships, and specimen infrastructure are starting to determine which prevention products become businesses and which remain science projects.
Read newsletter #4 →Newsletter #3 · Sep 1, 2026
Artificial-intelligence drug discovery, gene editing, cancer screening, and aging-biology companies now face the same test: can they turn technology into products that buyers, regulators, clinicians, and payers will act on?
Read newsletter #3 →Newsletter #2 · Aug 26, 2026
Blood draws, insurer pathways, lab reimbursement, artificial-intelligence screening workflows, and employer benefits show why healthspan businesses scale through access points as much as better tests.
Read newsletter #2 →Newsletter #1 · Aug 18, 2026
Premium prevention, reprogramming capital, a first-human epigenetic-restoration trial, insurance-supported women's midlife care, and Medicare access rules are turning longevity from aspiration into products, proof, payment, and buyer behavior.
Read newsletter #1 →